Here’s what you should know:
1. Despite a 19.7 percent year-over-year increase, the company’s revenues were lower than Zacks’ estimated $68.5 million.
2. Ironwood reported adjusted losses of $0.28 per share. The losses were higher than Zacks’ estimated $0.23 per share.
3. Ironwood’s key product Linzess generated $167.8 million in sales. As per an agreement, Ironwood splits Linzess sales with Allergan. Ironwood’s net profits from Linzess amounted to $43.8 million.
4. Linzess prescriptions increased 15 percent in the second quarter, surpassing 750,000.
More articles on gastroenterology:
Nevada Supreme Court overturns 2nd-degree murder conviction against gastroenterologist linked to Las Vegas hepatitis C outbreak — 4 insights
Olympus to pay $6.6M in duodenoscope-related damages — 6 key takeaways
Renewed interest in gastroparesis research brings cure into focus — 4 key notes
